LakeShore Biopharma has commenced the submission of its biologics license application (BLA) to the Drug Regulatory Authority ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

Advancing to first-in-human clinical trials requires formulation development to design a successful sterile formulation that ...

Mustang Bio has received orphan drug designation from the US Food and Drug Administration (FDA) for MB-108, a herpes simplex ...

Sonnet BioTherapeutics has announced the issuance of US Patent No. 12,134,635 covering its two new drug candidates, SON-1411 ...

Aurinia expects the downsizing of 45% will save it more than $40m in annual operating expenses. Credit: VectorMine via Shutterstock. Canadian biotech Aurinia Pharmaceuticals has announced it will be ...

Santen Pharmaceutical and Arctic Vision have signed a commercial collaboration agreement for the ARVN001to treat uveitic ...

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

In Canada pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.

In the global pharmaceutical industry, there were three private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.